Century Therapeutics Reports Q2 Results and Leadership Change

Century Therapeutics ( (IPSC) ) has issued an announcement.

On August 14, 2025, Century Therapeutics announced its second quarter financial results and business updates, highlighting ongoing patient dosing in the CALiPSO-1 trial and progress in IND-enabling studies for CNTY-308. The company extended its cash runway into the fourth quarter of 2027 following a workforce reduction and strategic focus on high-potential programs. CEO Brent Pfeiffenberger was appointed as Board Chair, succeeding Joe Jimenez, who will continue as a special advisor. The company remains on track to report clinical data for CNTY-101 by the end of 2025 and plans to initiate clinical studies for CNTY-308 in 2026.

The most recent analyst rating on (IPSC) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Spark’s Take on IPSC Stock

According to Spark, TipRanks’ AI Analyst, IPSC is a Neutral.

The stock score is primarily impacted by the company’s financial struggles and negative valuation metrics. Some technical indicators show neutral trends, but high beta suggests volatility. Recent corporate events provide mixed signals, with positive financial results but significant workforce reductions.

To see Spark’s full report on IPSC stock, click here.

More about Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on developing genetically engineered, iPSC-derived cell therapies for autoimmune diseases and cancers. The company aims to provide off-the-shelf cell therapies that expand patient access and advance the treatment of these conditions.

Average Trading Volume: 975,666

Technical Sentiment Signal: Sell

Current Market Cap: $44.63M

Find detailed analytics on IPSC stock on TipRanks’ Stock Analysis page.